UK startup Storm Therapeutics picks up Series A funds
UK-based Storm Therapeutics, which focuses on developing small molecule drugs that target RNA-modifying enzymes, has raised 12 million pounds in Series A funding. The investors were Imperial Innovations, Cambridge Innovation Capital, Merck Ventures and Pfizer Venture Investments.
28 June 2016•5 mins read
